These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 9605596)

  • 1. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
    Lüscher TF; Yang Z
    Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endothelium in coronary artery disease.
    Ruschitzka FT; Noll G; Lüscher TF
    Cardiology; 1997; 88 Suppl 3():3-19. PubMed ID: 9397288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection?
    Ferrari R
    J Hypertens Suppl; 1997 Mar; 15(2):S109-17. PubMed ID: 9218207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.
    Lüscher TF; Spieker LE; Noll G; Cosentino F
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of calcium antagonists in ischaemic heart disease.
    Pepine CJ
    Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function.
    d'Uscio LV; Shaw S; Barton M; Lüscher TF
    Hypertension; 1998 Jun; 31(6):1305-10. PubMed ID: 9622146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands.
    Morisco C; Lembo G; Sarno D; Argenziano L; Fratta L; Rozza F; Trimarco B
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S27-33. PubMed ID: 9605599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone.
    Lüscher TF
    Basic Res Cardiol; 1993; 88 Suppl 1():15-24. PubMed ID: 8357330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.